Evidence map›Paper›PMID 19934020›Full record

ArticleThe Journal of experimental medicine2009

Both XPD alleles contribute to the phenotype of compound heterozygote xeroderma pigmentosum patients.

Takahiro Ueda, Emmanuel Compe, Philippe Catez, Kenneth H Kraemer, Jean-Marc Egly

Open access · greenAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Clinical cancer research : an official journal of the American Association for Cancer Research · 2019
    Article
  14. Article
  15. Article
  16. Deep phenotyping of 89 xeroderma pigmentosum patients reveals unexpected heterogeneity dependent on the precise molecular defect.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Takahiro UedaInstitut de Génétique et de Biologie Moléculaire et Cellulaire, BP 10142, 67404 Illkirch Cedex, C.U. Strasbourg, France.
Emmanuel Compe
Philippe Catez
Kenneth H Kraemer
Jean-Marc Egly
Institut de génétique et de biologie moléculaire et cellulaire · FRCenter for Cancer Research · USInstitut de Recherche contre les Cancers de l’Appareil Digestif · FRNational Cancer Institute · US

Funding

DNA Repair in Human Cancer-Prone Genetic DiseasesZIABC004517 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KRAEMER, KENNETH H · 2009 to 2024
$26.5M
Intramural NIH HHS
6 · The paper itself

Abstract

Mutations in the XPD subunit of the DNA repair/transcription factor TFIIH result in the rare recessive genetic disorder xeroderma pigmentosum (XP). Many XP patients are compound heterozygotes with a "causative" XPD point mutation R683W and different second mutant alleles, considered "null alleles." However, there is marked clinical heterogeneity (including presence or absence of skin cancers or neurological degeneration) in these XPD/R683W patients, thus suggesting a contribution of the second allele. Here, we report XP patients carrying XPD/R683W and a second XPD allele either XPD/Q452X, /I455del, or /199insPP. We performed a systematic study of the effect of these XPD mutations on several enzymatic functions of TFIIH and found that each mutation exhibited unique biochemical properties. Although all the mutations inhibited the nucleotide excision repair (NER) by disturbing the XPD helicase function, each of them disrupted specific molecular steps during transcription: XPD/Q452X hindered the transactivation process, XPD/I455del disturbed RNA polymerase II phosphorylation, and XPD/199insPP inhibited kinase activity of the cdk7 subunit of TFIIH. The broad range and severity of clinical features in XP patients arise from a broad set of deficiencies in NER and transcription that result from the combination of mutations found on both XPD alleles.

Indexed as

AdultAllelesAnimalsCells, CulturedFemaleHeterozygoteHumansKruppel-Like Transcription FactorsMalePhenotypePoint MutationSpodopteraTranscription Factor TFIIHTranscription, GeneticXeroderma PigmentosumXeroderma Pigmentosum Group D ProteinERCC2 protein, humanKLF9 protein, humanKruppel-Like Transcription FactorsTranscription Factor TFIIHXeroderma Pigmentosum Group D Protein

Identifiers

PMID19934020
PMCPMC2806454
OpenAlexW2157353280

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.